Case 27

You are the Foundation Year 2 doctor working in General Medical Centre. Your GP supervisor is Dr Dolittle. Your bleep number is 2468.

Patient details

Patient name: Sarah Jane Date of birth: 18/08/1951 Patient number: X70785862

History

3 months ago Sarah Jane was discharged from St Elsewhere Hospital after a 6 week stay. She has been diagnosed with bipolar disease and was commenced on lithium by her psychiatrist 3 months ago.

She has attended the GP today to have bloods done for routine monitoring for her medication. Sarah reports no symptoms or side effects.

It is currently 9.30am and she recalls taking her last dose last night at 9.30pm. She is currently taking lithium carbonate 250mg. She has no recent bloods on the system for comparison.

Examination

Oxygen saturations: 99% (room air) Respiratory rate: 16bpm

Heart rate: 86bpm

Blood pressure: 118/74mmHg

Temperature: 36.9 C

Task

Please request the 3 most important blood tests to monitor the new medication.

Patient number: X7C	78 <i>5</i> 862	Clinical details:			
Surname: Jane		Forename: Sarah		(Incl. current antibiotic therapy)	
D.O.B.: 18/08/1951		Sex (please circle): M <u>F</u>		Routine monitoring of lithium medication for management of bipolar disorder. Currently on	
Ward: General Medical Centre		Consultant Dr Dolittle			
Specimen date: 04/05/2023 (Today's date)		Time: 09:30am		lithium carbonate 250mg. Last dose 12 hours ago.	
Requesting MO: Niamh Garratt (F2)		Bleep: 2468		Signature: N Garratt	
BIOCHEMISTRY		HAEMATOLOGY		MICROBIOLOGY / VIROLOGY	
 ☑ U/E ⊕ Bone profile ⊕ Liver profile ⊕ Gamma GT ⊕ Amylase ⊕ Ionised calcium ⊕ Magnesium ⊕ Urate ⊕ CRP 	 	# FBC # ESR # B12/Folate # Glandular fever screen # Haemoglobinopathy screen Other (specify):	 # INR # APTR # Coagulation screen # Thrombophilia screen 	 Specimen type: 	
# Ferritin # Immunoglobulins	# Cyclosporin # Tacrolimus		IMMUNOLOGY		
Other (specify):	+ Tacioninas		# Auto AB screen # Rh Factor	# Thyroid Microsomal Abs # Total IgE	
Lithium level			# ENA Abs # ANCA # DNA Abs	Other (<i>specify</i>):	

Answer

Drug monitoring blood tests is a classic examination question, but luckily the answers you need can nearly always be found in the BNF.

Serum concentrations

Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available.

Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4–1 mmol/litre (lower end of the range for maintenance therapy and elderly patients).

A target serum-lithium concentration of 0.8–1 mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have subsyndromal symptoms. It is important to determine the optimum range for each individual patient.

Monitoring of patient parameters

Manufacturer advises to assess renal, cardiac, and thyroid function before treatment initiation. An ECG is recommended in patients with cardiovascular disease or risk factors for it. Body-weight or BMI, serum electrolytes, and a full blood count should also be measured before treatment initiation.

Monitor body-weight or BMI, serum electrolytes, eGFR, and thyroid function every 6 months during treatment, and more often if there is evidence of impaired renal or thyroid function, or raised calcium levels. Manufacturer also advises to monitor cardiac function regularly.

Lithium has only a few parameters that the BNF states should be monitored; BMI, serum electrolytes, eGFR, and thyroid function every 6 months during treatment. Routine serum-lithium monitoring should be performed weekly after initiation and after each dose change until concentrations are stable, then every 3 months for the first year, and every 6 months thereafter.

Therefore, the 3 most appropriate bloods in this case are U&E for electrolytes and eGFR, TFTs for thyroid function, and a serum lithium level.

It is important that the sample for a serum lithium level is taken 12 hours after the dose to enable the concentration levels to be accurately monitored. In this case the timings of the last dose is stated in the question so it is a clinically relevant piece of information to include.